Lirilumab
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
Product Specifications
CAS Number
1000676-41-4
Product Name Alternative
IPH2102
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lirilumab.html
Purity
96.80
Solubility
10 mM in DMSO
Smiles
[Lirilumab]
Molecular Weight
(145.52 kDa)
References & Citations
[1]Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28 (3) :468-478.|[2]Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123 (5) :678-86.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY423245 100 µg
CYP4A22 (NM_001010969) Human Over-expression Lysate
Sign In for Pricing
View Details 
